The thyroid hormone triiodothyronine reinvigorates dendritic cells and potentiates anti-tumor immunity by Alamino, Vanina Alejandra et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=koni20
Download by: [T&F Internal Users], [Kevin Swanson] Date: 28 December 2015, At: 09:02
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: http://www.tandfonline.com/loi/koni20
The thyroid hormone triiodothyronine
reinvigorates dendritic cells and potentiates anti-
tumor immunity
V.A. Alamino, M.M. Montesinos, G.A. Rabinovich & C.G. Pellizas
To cite this article: V.A. Alamino, M.M. Montesinos, G.A. Rabinovich & C.G. Pellizas (2016) The
thyroid hormone triiodothyronine reinvigorates dendritic cells and potentiates anti-tumor
immunity, OncoImmunology, 5:1, e1064579, DOI: 10.1080/2162402X.2015.1064579
To link to this article:  http://dx.doi.org/10.1080/2162402X.2015.1064579
Accepted author version posted online: 01
Jul 2015.
Submit your article to this journal 
Article views: 11
View related articles 
View Crossmark data
AUTHOR’S VIEW
The thyroid hormone triiodothyronine reinvigorates dendritic cells and potentiates
anti-tumor immunity
V.A. Alaminoa, M.M. Montesinosa, G.A. Rabinovichb, and C.G. Pellizasa
aCentro de Investigaciones en Bioquımica Clınica e Inmunologıa (CIBICI-CONICET) and Departamento de Bioquımica Clınica, Facultad de Ciencias
Quımicas, Universidad Nacional de Cordoba, Cordoba, Argentina; bLaboratorio de Inmunopatologıa, Instituto de Biologıa y Medicina Experimental
(IBYME-CONICET) and Departamento de Quımica Biologica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires,
Argentina
ARTICLE HISTORY
Received 15 June 2015
Accepted 16 June 2015
ABSTRACT
Dendritic cell (DC) cancer vaccines have shown limited clinical benefit. Thus, the identification of signals
and molecular pathways that potentiate the immunogenicity of DCs has become a major challenge in
cancer research. Our studies demonstrate that triiodothyronine endows DCs with enhanced ability to





The immune and endocrine systems are interconnected via
bidirectional networks. This reciprocal cross-talk preserves
homeostasis in physiological conditions. This communication
is possible because both systems share common ligands (hor-
mones and cytokines) and their specific receptors. This
immune-endocrine circuit is evidenced by the immunological
consequences of primary endocrine disorders as well as by the
altered function of hormonal systems during immunopathol-
ogy. However, it also offers additional opportunities for thera-
peutic intervention.1
Dendritic cells (DCs), the main antigen-presenting cells, are
endowed with a unique capacity to recognize, process and pres-
ent antigens to naive T cells tailoring adaptive immunity. Inter-
estingly, DCs can process exogenous antigens and present
them in the context of major histocompatibility complex
(MHC) Class I molecules, a process termed "cross-presenta-
tion" crucial for the induction of protective immunity against
tumors. DC-based cancer immunotherapeutic strategies have
been widely used to engender CD8+ T-cell responses using
patients’ own DCs loaded with tumor-associated antigens ex
vivo. However, success of this therapeutic modality is still lim-
ited as activated DCs have a short half-life in lymph nodes, and
antigen processing and presentation in tumor-associated lymph
nodes may fuel tolerogenic rather than immunogenic T-cell
programs. Therefore, increasing DC survival and immunoge-
nicity represents a major challenge in vaccination strategies.2
Thyroid hormones (THs) are critical regulators of cellular dif-
ferentiation, growth, and metabolism. Thyroid-related patholo-
gies are the most common endocrine dysfunctions, and therefore
the study of TH action in different target cells is of crucial inter-
est. Cellular activity of THs usually requires the binding of the
active TH triiodothyronine (T3) to its nuclear receptors (TRs)
expressed as 4 major isoforms: TRa1, TRb1, TRb2 and TRb3.
However, nongenomic actions of THs have been recognized and
include the involvement of cytoplasmic TRs. TRb mutant
knock-in mice harboring a frame-shift mutation in the last 14
carboxy-terminal amino acids of TRb1 (termed TRPV) showed a
complete loss of T3-binding and transactivation activities. TRPV,
as well as other mouse models, has enabled the demonstration
that normal TRb could function as a tumor suppressor, avoiding
cancer development, progression, and metastasis.3
The direct effects of THs on T cells have been largely studied
in both primary T lymphocytes and lymphoma T-cell lines.4
However, the impact of THs in the initiation of adaptive
immune responses is poorly understood. We have shown that
expression of TRs, surprisingly the cytoplasmic b1 isoform,
contributes to DC maturation and Th1-type cytokine secretion
induced by physiologic levels of T3. We found that T3-stimu-
lated DCs favored IFN-g secretion by CD4+ and CD4¡ T cells.5
These effects involved activation of Akt- and NF-kB-dependent
pathways 6 and were counteracted by glucocorticoids.7
In a recent issue of Cancer Research 8 we demonstrated that
the immunostimulatory effects of T3 were abrogated in DCs
isolated from TRPV mice, emphasizing the requirement for an
intact TRb-T3 signaling axis in T3-induced DC activation.
Taken together, these findings, the tumor suppressor role of
TRb3 and the increased IFNg production by CD4¡ T cells
induced by allogeneic T3-treated DCs 5, prompted us to investi-
gate the role of T3 in tumor immunity.
Does T3 reshape DCs and modulate antigen-specific
T-cell cytotoxicity?
In our recent study8, we revealed that T3 instructs DCs to stim-
ulate antigen-specific cytotoxic responses as shown by in vivo
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cytotoxicity and in vitro antigen cross-presentation assays.
These effects were accomplished by a T3-dependent increase in
DC viability. This finding reinforces our previous results show-
ing a T3-dependent induction of Akt activation in DCs 6, as
Akt phosphorylation enhances DC survival. 9 In addition, our
new studies revealed that T3 ameliorates the DC capacity to
migrate to lymph nodes and favors the expression of CCR7, an
essential receptor for DC homing to lymph nodes.10 Altogether,
these data demonstrate the ability of T3-conditioned DCs to
potentiate antitumor immunotherapeutic strategies.
Finally, our report 8 showed that T3-conditioned OVA-
pulsed DCs delayed growth of B16-OVA tumors in vivo, pro-
longed survival of tumor-bearing mice and increased the per-
centage of tumor-free mice, in part by promoting the
expansion and/or differentiation of IFNg-producing CD8+ T
cells at sites of tumor growth (Fig. 1).
In conclusion, our findings suggest a novel mechanism by
which the T3-TRb complex influences antitumor responses by
bolstering DC-mediated T-cell activation during tumor growth.
Although the influence of T3 on DC immunogenicity needs to
be evaluated in other tumor models, our results establish the
first evidence of an adjuvant effect of T3-TRb signaling on
DCs, suggesting an applicable method to empower DC vaccina-
tion either alone or in combination with other cancer immuno-
therapeutic strategies, including the blockade of inhibitory
checkpoints (CTLA4, PD-1/PD-L1, LAG3, etc).
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Figure 1. Triiodothyronine instructs DCs to stimulate T-cell mediated antitumor responses. Triiodothyronine (T3 ) binding to thyroid hormone receptor (TR)-b increases
dendritic cell (DC) viability and T cell-stimulatory capacity, and potentiates the ability of DCs to cross-present antigens. In a mouse model of melanoma, vaccination with
T3-stimulated DCs in the presence of a tumor antigen, favors the migratory capacity of these cells to lymph nodes where they present antigens to na€ıve T cells and pro-
mote the activation of tumor-specific effector T cells. These cells migrate into the tumor to boost the development of a specific cytotoxic immune response mediated by
IFN-g-producing CD8+ T cells, which ultimately restrain tumor growth and prolong host survival.
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